Subscribe
14 February 2013Americas

Bristol-Myers Squibb loses Baraclude patent fight with Teva

A US judge has invalidated pharmaceutical company Bristol-Myers Squibb (BMS)’s patent covering its hepatitis B treatment Baraclude, agreeing with generic manufacturer Teva Pharmaceuticals that the invention of the active compound in the drug was obvious to anyone skilled in medicinal chemistry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva wins appeal over thyroid drug at Fed Circuit
10 August 2020   In a victory for Teva Pharmaceuticals, the US Court of Appeals for the Federal Circuit dismissed IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Teva wins appeal over thyroid drug at Fed Circuit
10 August 2020   In a victory for Teva Pharmaceuticals, the US Court of Appeals for the Federal Circuit dismissed IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.

More on this story

Big Pharma
Teva wins appeal over thyroid drug at Fed Circuit
10 August 2020   In a victory for Teva Pharmaceuticals, the US Court of Appeals for the Federal Circuit dismissed IBSA Institut Biochimique’s appeal against a ruling that held parts of its patent invalid.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?